Olema Pharmaceuticals (OLMA) Accounts Payables (2020 - 2026)

Olema Pharmaceuticals (OLMA) has 7 years of Accounts Payables data on file, last reported at $3.7 million in Q1 2026.

• Accounts Payables for Q1 2026 came in at $3.7 million, up 2362.91% year-over-year; the trailing twelve-month figure through Mar 2026 was $3.7 million (up 2362.91% YoY), and the FY2025 annual result was $9.3 million, up 107.47% from the prior year.
• Accounts Payables declined to $3.7 million in Q1 2026 per OLMA's latest filing, from $9.3 million in the prior quarter.
• Over five years, Accounts Payables peaked at $9.3 million in Q4 2025 and troughed at $14000.0 in Q3 2022.
• A 5-year average of $2.6 million and a median of $2.2 million in 2023 frame the typical range for Accounts Payables.
• The sharpest annual moves came in 2023 and 2025: Accounts Payables soared 15664.29% in 2023, then tumbled 98.03% in 2025.
• A 5-year view of Accounts Payables shows it stood at $374000.0 in 2022, then jumped by 621.39% to $2.7 million in 2023, then jumped by 65.31% to $4.5 million in 2024, then soared by 107.47% to $9.3 million in 2025, then tumbled by 59.81% to $3.7 million in 2026.
• Business Quant data shows OLMA's Accounts Payables at $3.7 million in Q1 2026, $9.3 million in Q4 2025, and $3.5 million in Q3 2025.